Moreover, we show that BCL-xL/miR-377 regulation in diffuse large B-cell lymphoma (DLBCL) cells drives acquired therapeutic resistance to ABT-199 and is associated with advanced tumor stage in CLL patients. Here, BCL2L1 is linked to neoplasm.